• mayukh.bhattacharyya@helmholtz-hips.de

LTM-produced antibiotics, as well as potential effects on the microbiome, toxicity, immune response, and drug metabolism.

• simone.rosinus@helmholtz-hips.de
• +49 68198806-4860

product antibiotics, the investigation of pharmacokinetics, and the assessment of synergistic effects of drug combinations. She is also working on the validation of screening tools and the chemical optimization

• angela.sester@helmholtz-hips.de
• +49-681-98806-5520

Dortmund University under Prof. Dr. Markus Nett, where she mainly investigated myxobacteria for new drug classes. As a postdoc at the TU Dresden with Prof. Dr. Tobias A. M. Gulder, the research focus shifted

• sidra.eisa@helmholtz-hips.de
• +49 6819 8806-2052

Later, she pursued her PhD at HIPS under the supervision of Prof. Anna Hirsch at the Department of Drug Design and Optimization, working on the synthesis of novel inhibitors targeting underexplored bacterial

• qingyuan.liu@helmholtz-hips.de

generative models to design novel protein sequences and applies explainable AI (XAI) techniques to Drug-Target Interaction (DTI) models. These efforts aim to identify critical protein residues, enabling

• Andreas.Kany@helmholtz-hips.de
• +4968198806-2051

vitro ADMET profiling. In 2022, he received a DAAD scholarship for a 4 months postdoc exchange at the Drug Discovery Unit, Dundee. He now holds a scientist position at HIPS being responsible for the coordination

• florian.hubrich@helmholtz-hips.de
• +49 6813-0270320

Florian Hubrich moved to Switzerland and worked for the Bachem AG, a world leading company for peptide drug manufacturing, as project chemist for analytical method development and group leader for in-process

• Sari.Rasheed@helmholtz-hips.de
• +4968198806-3131

on anti-tubercular agents. Dr. Rasheed is currently among the managing team of the Natural Product Drug Discovery Project funded by the Bill & Melinda Gates Foundation and is coordinating biological screening

• anna-lisa.klein@helmholtz-hips.de
• +49 681 98806 3034

system for the zebrafish larvae toxicity model. This system aims to detect toxic side effects of drug candidates at an early stage. In the future, this should facilitate preclinical research on natural

• Carsten.Volz@helmholtz-hips.de
• +4968198806-3032

exciting biological activities. Many of these compounds can potentially be developed into powerful drugs against a number of diseases. Nevertheless, biosynthesis of biologically active compounds is commonly